MCID: PTT037
MIFTS: 42

Pituitary Tumors

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pituitary Tumors

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 52 53 41
Pituitary Neoplasms 71
Pituitary Tumor 58

Classifications:



External Ids:

UMLS via Orphanet 72 C0032019
Orphanet 58 ORPHA304055
UMLS 71 C0032019

Summaries for Pituitary Tumors

NINDS: 52 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary: Pituitary Tumors, also known as pituitary neoplasms, is related to multiple endocrine neoplasia, type iv and empty sella syndrome. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Adipogenesis and Growth hormone receptor signaling. The drugs Hydrocortisone succinate and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and hypothalamus, and related phenotypes are nervous system and homeostasis/metabolism

MedlinePlus: 41 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include: Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iv 31.4 MEN1 GNAS
2 empty sella syndrome 31.3 PROP1 PRL IGF1 GH1
3 pituitary-dependent cushing's disease 31.2 SST PRL GH1
4 pituitary adenoma 1, multiple types 31.1 SST PRL MEN1 IGF1 GH1
5 galactorrhea 30.8 PRL IGF1
6 central diabetes insipidus 30.5 PRL IGF1 GH1
7 hormone producing pituitary cancer 30.5 SSTR5 SST PRL MEN1 IGF1 GNAS
8 chromophobe adenoma 30.5 PRL GH1
9 nelson syndrome 30.4 SSTR5 SST PRL
10 hypopituitarism 30.4 PROP1 PRL IGF1 GH1
11 hyperprolactinemia 30.4 SST PRL IGF1 GNAS GH1
12 neuroendocrine tumor 30.3 SST MEN1 IGF1
13 precocious puberty 30.2 GNAS GH1
14 pituitary apoplexy 30.1 SST PRL IGF1 GH1
15 tsh producing pituitary tumor 30.0 SSTR5 SST PRL
16 pituitary hormone deficiency, combined, 2 30.0 PROP1 PRL IGF1 GH1
17 hypogonadism 30.0 PROP1 PRL IGF1 GH1
18 chiasmal syndrome 29.9 SST PRL
19 ectopic cushing syndrome 29.9 SST PRL
20 hyperthyroidism 29.9 SST PRL IGF1 GNAS GH1
21 gangliocytoma 29.9 SST PRL
22 insulin-like growth factor i 29.9 SST PRL IGF1 GH1
23 acth-secreting pituitary adenoma 29.8 SSTR5 SST PRL MEN1
24 multiple endocrine neoplasia, type i 29.8 SST PRL MEN1 GNAS CNC2
25 pituitary adenoma 29.8 SSTR5 SST PTTG1 PRL MEN1 IGF1
26 craniopharyngioma 29.8 PTTG1 PROP1 PRL IGF1 GH1
27 adenoma 29.8 SSTR5 SST PTTG1 PRL MEN1 IGF1
28 hypothyroidism, central, with testicular enlargement 29.8 PROP1 PRL
29 pituitary hypoplasia 29.7 PROP1 PRL IGF1
30 multiple endocrine neoplasia 29.7 SST PRL MEN1 GNAS CNC2
31 carcinoid syndrome 29.7 SST IGF1
32 polycystic ovary syndrome 29.6 PRL IGF1 GH1
33 hypoglycemia 29.6 SST PRL IGF1 GH1
34 conn's syndrome 29.6 SST PRL MEN1 IGF1 GNAS GH1
35 carcinoid tumors, intestinal 29.5 SST MEN1
36 goiter 29.5 SST PRL IGF1 GNAS
37 hypothalamic disease 29.5 PRL IGF1 GH1
38 meningioma, familial 29.4 SSTR5 SST PRL MEN1 IGF1
39 insulinoma 29.4 SSTR5 SST MEN1 GH1
40 hypothyroidism 29.4 SST PROP1 PRL IGF1 GNAS GH1
41 primary hyperparathyroidism 29.3 PRL MEN1 GH1
42 acromegaly 29.3 SSTR5 SST PRL MEN1 IGF1 GNAS
43 thyroid carcinoma, familial medullary 29.2 SSTR5 SST MEN1
44 pheochromocytoma 29.2 SST PRL MEN1 IGF1
45 prolactinoma 29.2 SSTR5 SST PTTG1 PRL MEN1 IGF1
46 thyroid gland medullary carcinoma 29.2 SST MEN1
47 hypothyroidism, congenital, nongoitrous, 4 29.2 PROP1 PRL IGF1 GH1
48 hypogonadotropic hypogonadism 29.1 PROP1 PRL IGF1
49 prolactin producing pituitary tumor 29.1 SSTR5 PRL MEN1 IGF1
50 mccune-albright syndrome 29.0 SST PRL MEN1 IGF1 GNAS GH1

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.11 GH1 GNAS IGF1 MEN1 PRL PROP1
2 homeostasis/metabolism MP:0005376 10.1 GH1 GNAS IGF1 MEN1 PRL PROP1
3 growth/size/body region MP:0005378 10.02 GH1 GNAS IGF1 MEN1 PROP1 PTTG1
4 endocrine/exocrine gland MP:0005379 9.97 GH1 GNAS IGF1 MEN1 PRL PROP1
5 adipose tissue MP:0005375 9.91 GH1 GNAS IGF1 PTTG1 RB1 SST
6 behavior/neurological MP:0005386 9.91 GH1 GNAS MEN1 PRL PROP1 PTTG1
7 neoplasm MP:0002006 9.88 GNAS IGF1 MEN1 PRL RB1
8 immune system MP:0005387 9.76 GH1 GNAS IGF1 MEN1 PRL PTTG1
9 respiratory system MP:0005388 9.43 GH1 GNAS IGF1 MEN1 PROP1 RB1
10 reproductive system MP:0005389 9.17 GH1 IGF1 MEN1 PRL PROP1 PTTG1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Ibuprofen Approved Phase 4 15687-27-1 3672
7
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
8
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
11
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
12
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
13
Cefuroxime Approved Phase 4 55268-75-2 5479529
14
Cefdinir Approved Phase 4 91832-40-5 6915944
15
Cefazolin Approved Phase 4 25953-19-9 33255
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Sulfamethoxazole Approved Phase 4 723-46-6 5329
18
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
19
Quinagolide Approved, Investigational Phase 4 87056-78-8
20
Cabergoline Approved Phase 4 81409-90-7 54746
21
Lactitol Approved, Investigational Phase 4 585-86-4 157355
22
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
23
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27 Hydrocortisone 17-butyrate 21-propionate Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29 Gastrointestinal Agents Phase 4
30 Antirheumatic Agents Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4
33 Analgesics, Opioid Phase 4
34 Narcotics Phase 4
35 Folate Phase 4
36 Vitamin B9 Phase 4
37 Vitamin B Complex Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Folic Acid Antagonists Phase 4
41 Cephalosporins Phase 4
42
Cefuroxime axetil Phase 4 3379942
43 Anti-Infective Agents Phase 4
44 Antiprotozoal Agents Phase 4
45 Antiparasitic Agents Phase 4
46 Antimalarials Phase 4
47 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
48 Cytochrome P-450 Enzyme Inhibitors Phase 4
49
Clindamycin phosphate Phase 4 32603
50 Clindamycin palmitate Phase 4

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
4 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor;IV Placebo
5 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
6 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
7 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
8 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
9 The Effects of Infraorbital Nerve Block With Dexmedetomidine Added to Bupivacaine on Fentanyl Requirement During Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor: Prospective Randomized Double Blinded Control Study Not yet recruiting NCT04785222 Phase 4 dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
10 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
11 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
12 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
13 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
14 Comparison Between Hemodynamic Effect of Bilateral Infraorbital Block Versus Intranasal Application of Bupivacaine in Patients Undergoing Transsphenoidal Pituitary Adenoma Resection.A Comparative Randomized Controlled Study Recruiting NCT05301634 Phase 3
15 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
16 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
17 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Terminated NCT02419664 Phase 3 Gallium-68 DOTATOC PET
18 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
19 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
20 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
21 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
22 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab
23 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease Recruiting NCT04339751 Phase 2 Vorinostat
24 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
25 Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery Not yet recruiting NCT05005715 Phase 2 Dexmedetomidine;normal saline
26 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Terminated NCT02749227 Phase 2 Pasireotide LAR
27 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
28 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
29 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Terminated NCT03930771 Phase 2 Capecitabine;Temozolomide
30 An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
31 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
32 Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial Withdrawn NCT04863339 Phase 2 Tranexamic acid;Placebo
33 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
34 Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT Unknown status NCT03404414 Phase 1 18F-FDG
35 Detection of Pituitary Neuroendocrine Tumor (PitNET) Tissue During Endoscopic Transsphenoidal Surgery Using Bevacizumab-800CW Recruiting NCT04212793 Phase 1 Bevacizumab-IRDye800CW
36 Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study Active, not recruiting NCT03465618 Phase 1 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
37 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Terminated NCT02629549 Phase 1 OTL38
38 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
39 Genome-wide Association Study of Pituitary Tumors Unknown status NCT01442220
40 PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France) Unknown status NCT02854228
41 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
42 A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas Unknown status NCT03309319 Rosiglitazone
43 Extended Support Within a Person-centred Practice After Surgery: a Quasi- Experimental Study for Persons With Pituitary Tumours Unknown status NCT03927183
44 Molecular Imaging of Pituitary Adenomas Unknown status NCT03815838
45 The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma Unknown status NCT03714763 Drug treatment
46 Withholding Hydrocortisone vs Routine Use of Hydrocortisone During Peri-operation in Pituitary Adenoma Patients With Intact Hypothalamus-Pituitary-Adrenal Axis: Randomized Controlled Trial to Assess Safety and Complications Unknown status NCT04621565 Normal saline;Hydrocortisone
47 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) vs. Tramadol in Pain Management After Transnasal Transsphenoidal Surgery Among Patients With Pituitary Adenomas: A Prospective Randomized Controlled Trial Unknown status NCT04611685 NSAID;Tramadol
48 Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests in Patients Undergoing Endoscopic Endonasal Transsphenoidal Surgery of Pituitary Gland Unknown status NCT02709863 Sevoflurane;Desflurane;Propofol
49 Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery: A Single-blinded Randomized Controlled Trial Unknown status NCT03773705
50 Prospective MRI Evaluation of Cavernous Sinus Invasion by Pituitary Adenoma Using Deep Learning Based Denoising Unknown status NCT04268251

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

Organs/tissues related to Pituitary Tumors:

MalaCards : Pituitary, Adrenal Gland, Hypothalamus, Thyroid, Brain, Testes, Breast

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 7278)
# Title Authors PMID Year
1
Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors. 41
36435867 2022
2
Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors. 41
36465639 2022
3
Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action. 41
36389809 2022
4
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. 53 62
20233783 2010
5
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. 53 62
20406982 2010
6
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 53 62
20106827 2010
7
The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. 53 62
20068168 2010
8
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. 53 62
19890024 2010
9
Effect of PTTG on endogenous gene expression in HEK 293 cells. 53 62
19958546 2009
10
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. 53 62
19837943 2009
11
Acromegaly pathogenesis and treatment. 53 62
19884662 2009
12
Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. 53 62
19637311 2009
13
Somatostatin analog and pegvisomant combination therapy for acromegaly. 53 62
19763127 2009
14
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. 53 62
19549593 2009
15
Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. 53 62
19528243 2009
16
Familial pituitary tumor syndromes. 53 62
19564887 2009
17
Pituitary enlargement in patients with PROP1 gene inactivating mutation represents cystic hyperplasia of the intermediate pituitary lobe. Histopathology and over 10 years follow-up of two patients. 53 62
19774847 2009
18
Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. 53 62
19687170 2009
19
Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells. 53 62
19359387 2009
20
Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. 53 62
19401364 2009
21
Novel oncogenic actions of TRbeta mutants in tumorigenesis. 53 62
19391168 2009
22
PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. 53 62
19351864 2009
23
Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine test. 53 62
19636202 2009
24
Spindle cell oncocytoma of the adenohypophysis: report of a case with marked cellular atypia and recurrence despite adjuvant treatment. 53 62
19353839 2009
25
Intrapituitary expression and regulation of the gp130 cytokine interleukin-6 and its implication in pituitary physiology and pathophysiology. 53 62
19236332 2009
26
RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. 53 62
19020999 2009
27
Activin, TGF-beta and menin in pituitary tumorigenesis. 53 62
20175454 2009
28
Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. 53 62
18791324 2009
29
Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly. 53 62
19420816 2009
30
Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. 53 62
19318729 2009
31
The effects of hyperprolactinemia on bone and fat. 53 62
18338266 2009
32
The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. 53 62
18752070 2009
33
The molecular biology of pituitary tumors: a personal perspective. 53 62
19058014 2009
34
Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. 53 62
19188737 2009
35
Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. 53 62
18787049 2008
36
Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. 53 62
19169048 2008
37
p21(Cip1) restrains pituitary tumor growth. 53 62
18981426 2008
38
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. 53 62
18708436 2008
39
Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. 53 62
18715881 2008
40
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. 53 62
18653781 2008
41
Hypophysectomy for prostate cancer: a revival of old knowledge? 53 62
18826367 2008
42
Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. 53 62
18539008 2008
43
Metabolic implications of growth hormone therapy. 53 62
19020393 2008
44
Estrogen receptors in human pituitary tumors. 53 62
18398784 2008
45
Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. 53 62
18492755 2008
46
Effect of hyperprolactinemia during development in children and adolescents. 53 62
18816151 2008
47
In vitro testing of new somatostatin analogs on pituitary tumor cells. 53 62
18243520 2008
48
Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. 53 62
18230656 2008
49
Levonorgestrel antagonism on estrogen-induced pituitary tumors is mediated by progesterone receptors. 53 62
18548383 2008
50
Management of acromegaly: is there a role for primary medical therapy? 53 62
18163213 2008

Variations for Pituitary Tumors

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

Pathways related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.92 RB1 IGF1 GH1
2
Show member pathways
10.55 PRL GH1

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.92 PRL GH1

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myoblast differentiation GO:0045445 9.46 RB1 IGF1
2 positive regulation of transcription regulatory region DNA binding GO:2000679 9.26 RB1 IGF1
3 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.92 IGF1 GH1

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.46 IGF1 GNAS
2 prolactin receptor binding GO:0005148 9.26 PRL GH1
3 hormone activity GO:0005179 9.23 SST PRL IGF1 GH1

Sources for Pituitary Tumors

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....